Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Avalo Therapeutics (AVTX) Accumulated Depreciation & Amortization (2016 - 2025)

Avalo Therapeutics' Accumulated Depreciation & Amortization history spans 12 years, with the latest figure at $253000.0 for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 64.37% year-over-year to $253000.0; the TTM value through Dec 2025 reached $253000.0, down 64.37%, while the annual FY2025 figure was $253000.0, 64.37% down from the prior year.
  • Accumulated Depreciation & Amortization reached $253000.0 in Q4 2025 per AVTX's latest filing, down from $710000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $710000.0 in Q4 2024 to a low of $253000.0 in Q4 2025.
  • Average Accumulated Depreciation & Amortization over 5 years is $441000.0, with a median of $414000.0 recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 61.58% in 2021, then crashed 64.37% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $286000.0 in 2021, then soared by 44.76% to $414000.0 in 2022, then skyrocketed by 30.92% to $542000.0 in 2023, then skyrocketed by 31.0% to $710000.0 in 2024, then plummeted by 64.37% to $253000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Accumulated Depreciation & Amortization are $253000.0 (Q4 2025), $710000.0 (Q4 2024), and $542000.0 (Q4 2023).